Clinical Trials Browser

Has results × trifluridine tipiracil drug combination × 1 year × Clear all

NCT05064059 2026-05-26

MK-4280A-007

Phase 3 Completed

441 enrolled 24 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT03686488 2026-03-02

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Phase 2 Completed

23 enrolled 12 charts

Gastrointestinal

Stomach Neoplasms

NCT04109924 2026-02-10

TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study

Phase 2 Completed

42 enrolled 12 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT04776148 2026-02-05

MK-7902-017

Phase 3 Completed

563 enrolled 32 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT04457297 2026-01-21

ALTAIR

Phase 3 Completed

243 enrolled 13 charts

Gastrointestinal

Digestive System Diseases, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Colorectal Neoplasms

NCT04417699 2025-12-10

SHORT

Phase 2 Completed

13 enrolled 12 charts

Gastrointestinal

Rectal Neoplasms

NCT05600309 2025-11-26

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

Phase 3 Completed

94 enrolled 15 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms